Immunogenicity and safety of a single dose of a CRM-conjugated meningococcal ACWY vaccine in children and adolescents aged 2-18 years in Taiwan: results of an open label study.

•MenACWY-CRM is a quadrivalent meningococcal conjugate vaccine.•This is the first study to assess MenACWY-CRM immunogenicity in Taiwan.•A single dose of MenACWY-CRM demonstrated a robust immune response.•MenACWY-CRM was well-tolerated.